Full ACHIEVE-4 results for orforglipron in type 2 diabetes, shown at EASD in Milan and in The Lancet, also report weight loss and lower blood pressure and triglycerides.
Recap by typeshit. Full story at Cardiovascular Business.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
In 2,749 people with type 2 diabetes, the daily pill also beat insulin on blood sugar and weight, though 62% reported stomach side effects. Results were presented at EASD.
Polskie Radio covers the FDA clearing Lilly's Zepbound to treat obstructive sleep apnea, an earlier approval beyond weight loss.
Loading…